FDA Okays Weekly Option in Achondroplasia - Top_Thought_Leaders - MDSpire

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

Top Thought Leaders in Urology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Usefulness of ultrasound in diagnosing constipation in children: a narrative review

Using the NASSS–Complexity Assessment Tool to Evaluate the Implementation of “Cadê O Kauê?”: Chat-Story Intervention for Youth Participation in Mental Health Promotion in Brazil